Better Therapeutics, Inc.

Better Therapeutics, Inc. (Nasdaq: BTTX) is a prescription digital therapeutics company focused on cognitive behavioral therapy-based treatments for cardiometabolic diseases, including type 2 diabetes. The company became publicly traded in 2022 following its merger with Mountain Crest Acquisition Corp. II, a blank-check vehicle sponsored by Mountain Crest Capital LLC, which had completed its IPO in 2021. Better Therapeutics operates in the health-technology and digital-health sector, developing software-based, FDA-regulated prescription therapeutics intended to address the root behavioral causes of chronic metabolic conditions. The March 2024 Form 424B3 prospectus supplement represents a post-merger capital markets filing under the company's active shelf registration. For full filing history, pipeline data, and SPAC transaction details on BTTX, sign up for complete access at SpacDesk.